RESEARKA

In a preclinical study by Correia-Melo and colleagues, the effects of rapamycin on healthspan and frailty were investigated in nfκb1 −/− mice, a model of accelerated aging and chronic inflammation. The study compared nfκb1 −/− mice fed a control diet (n = 44) with those receiving rapamycin-supplemented feed. Translational relevance to humans remains uncertain. A key finding was that rapamycin treatment prevented age-related frailty in these mice, as evidenced by significant differences in frailty scores (P < 0.01, P < 0.001) between the groups over the study duration. Translational relevance to humans remains uncertain. However, this improvement in healthspan metrics occurred without a corresponding extension of lifespan, highlighting a dissociation between functional outcomes and longevity in this model.

Citation Support

• source_1 Mandrioli 2023
• source_2 Lin 2022
• source_3 Moel 2025
• source_4 Gkioni 2025
• source_5 Zhou 2024